Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345991 | 0.76 | MME (0.55) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7345996 | 0.76 | MME (0.55) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1562300 | 0.75 | XIAP (0.48) | TSHRHTTKMT2AXIAPALDH1A1 | |
| SCHEMBL7473291 | 0.74 | TSHR (0.54) | TSHRHTTMEN1KMT2AXIAP | |
| SCHEMBL1562017 | 0.73 | AADAT (0.41) | TSHRHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL30036591 | 0.73 | AADAT (0.41) | TSHRHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL19592502 | 0.73 | AADAT (0.41) | TSHRHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL5551997 | 0.72 | TSHR (0.40) | TSHRHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL8555694 | 0.69 | ALDH1A1 (0.46) | TSHRGSK3BALDH1A1SMN1; SMN2ADK | |
| SCHEMBL9270527 | 0.68 | XIAP (0.53) | TSHRHTTMEN1KMT2AXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828151-B1 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-1828151-A2 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7211573-B2 | Malonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2006061136-A2 | MALONAMIDE DERIVATIVES AS INHIBITORS OF GAMMA-SECRETASE FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122168-A1 | Malonamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122168-A1 | Malonamide derivatives | ACE, REN, ME1 | TSHR 1637/4885HTT 192/4885MEN1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.